コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 DX; and (iv) xenografts of Ewing sarcoma and rhabdomyosarcoma.
2 d and proliferative phenotypes for embryonal rhabdomyosarcoma.
3 ' tumour, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
4 cause cancer, for example, breast cancer or rhabdomyosarcoma.
5 ncers, but little is known about its role in rhabdomyosarcoma.
6 holds promise for the treatment of alveolar rhabdomyosarcoma.
7 tizer for the clinical treatment of alveolar rhabdomyosarcoma.
8 rognosis for invasive or metastatic alveolar rhabdomyosarcoma.
9 essential component of therapy for alveolar rhabdomyosarcoma.
10 therapeutic targets for high-risk embryonal rhabdomyosarcoma.
11 fusion gene status to risk stratify alveolar rhabdomyosarcoma.
12 ation of dystrophies to the childhood cancer rhabdomyosarcoma.
13 ites and associated target genes in alveolar rhabdomyosarcoma.
14 evaluation of agents against this aggressive rhabdomyosarcoma.
15 expressed myogenic markers, consistent with rhabdomyosarcoma.
16 associated with the development of alveolar rhabdomyosarcoma.
17 target these pathways in the childhood tumor rhabdomyosarcoma.
18 ll leukemia, pancreatic cancer, melanoma and rhabdomyosarcoma.
19 the pediatric solid tumors, osteosarcoma and rhabdomyosarcoma.
20 e prognosis of PAX3-FOXO1 fusion in alveolar rhabdomyosarcoma.
21 improve survival for patients with high-risk rhabdomyosarcoma.
22 improve survival in patients with high-risk rhabdomyosarcoma.
23 representing a therapeutic vulnerability of rhabdomyosarcoma.
24 s in vitro and in a virally induced model of rhabdomyosarcoma.
25 06B-BRAF), and a novel PAX3-GLI2 fusion in a rhabdomyosarcoma.
26 histopathology concluded the tissue to be a rhabdomyosarcoma.
27 ising viable therapeutic option for advanced rhabdomyosarcoma.
28 anisation of the fused landscape in alveolar rhabdomyosarcoma.
29 m his father for the treatment of metastatic rhabdomyosarcoma.
30 rk with critical therapeutic implications in rhabdomyosarcoma.
31 ved significantly, especially for metastatic rhabdomyosarcoma.
32 samples also confirmed their specificity to rhabdomyosarcoma.
33 and tumor and bone marrow biopsies disclosed rhabdomyosarcoma.
34 contributes to the differentiation defect in rhabdomyosarcomas.
35 he contribution of two microRNAs (miRNAs) in rhabdomyosarcomas.
36 role for these miRNAs in the development of rhabdomyosarcomas.
37 ng 24 neuroblastomas, 24 Wilms tumors, and 8 rhabdomyosarcomas.
41 relapsed high-risk neuroblastoma, embryonal rhabdomyosarcoma, acute myeloid leukemia, and relapsed a
42 y tumour (head and neck anaplastic embryonal rhabdomyosarcoma), all patients were alive at the time o
43 KCiota is functionally important in alveolar rhabdomyosarcoma anchorage-independent growth and tumor-
44 as single agents in both zebrafish embryonal rhabdomyosarcoma and a human cell line of rhabdomyosarco
45 evant distinction in PDGF signaling in human rhabdomyosarcoma and also suggests continued exploration
46 atients with first relapse or progression of rhabdomyosarcoma and an unfavorable prognosis were rando
47 ul reagent for studies of myasthenia gravis, rhabdomyosarcoma and arthrogryposis multiplex congenita
48 ced complete remissions in one model each of rhabdomyosarcoma and EWS, and in three of four osteosarc
49 med whole-genome and RNA sequencing on human rhabdomyosarcoma and identified RAS mutations and oxidat
50 , we define the core regulatory circuitry of rhabdomyosarcoma and identify critical CR TF dependencie
51 amily tyrosine kinase YES1 is upregulated in rhabdomyosarcoma and is necessary for growth, but clinic
52 the protein level in primary EFT but not in rhabdomyosarcoma and neuroblastoma, and EFT cells exhibi
54 monstrate a novel oncogenic role for PAK4 in rhabdomyosarcoma and show that targeting PAK4 activity i
56 ng allows improved diagnosis of experimental rhabdomyosarcoma and therefore might influence clinical
57 A-damaging agent as an effective therapy for rhabdomyosarcoma and visualized therapeutic responses us
59 pitulate gene-expression signatures of human rhabdomyosarcomas and identified a cluster of genes that
60 expression of HOTS inhibits Wilms, rhabdoid, rhabdomyosarcoma, and choriocarcinoma tumor cell growth,
61 s (48, three, and one with DSRCT, peritoneal rhabdomyosarcoma, and Ewing sarcoma, respectively) recei
64 ipoliovirus immunity (n = 17) on Vero, human rhabdomyosarcoma, and human epidermoid carcinoma 2 cells
66 icular germ-cell tumors, in 2 of 5 embryonal rhabdomyosarcomas, and in 1 of 266 epithelial ovarian an
69 essful purification of RNA from the alveolar rhabdomyosarcoma (ARMS) cancer cell line, with 3.5-fold
77 The highly aggressive muscle cancer alveolar rhabdomyosarcoma (ARMS) is one of the most common soft t
78 e 2;13 chromosomal translocation in alveolar rhabdomyosarcoma (ARMS), a cancer associated with the sk
79 velopment and is a key component in alveolar rhabdomyosarcoma (ARMS), a childhood solid muscle tumor.
80 t the concept into use, we selected alveolar rhabdomyosarcoma (ARMS), a myogenic pediatric cancer who
81 transcription factor, which induces alveolar rhabdomyosarcoma (aRMS), an aggressive cancer of skeleta
82 dismal for patients with metastatic alveolar rhabdomyosarcoma (aRMS), where the chimeric transcriptio
85 protein is present in a majority of alveolar rhabdomyosarcomas associated with increased aggressivene
86 nd young adults (age range, 1-18 years) with rhabdomyosarcoma at two institutions (1999-2009) with re
88 nd mTOR-signaling pathways are implicated in rhabdomyosarcoma biology, and hence are promising therap
90 ferentiation and tumorigenesis, can classify rhabdomyosarcomas by clinical subtype, and can predict p
91 nic differentiation can be induced in the RD rhabdomyosarcomas by increasing the abundance of MyoD:E-
93 show that the mechanisms regulating YAP1 in rhabdomyosarcoma can be inhibited by combinatorial thera
95 ppo-independent regulation of YAP1, ablating rhabdomyosarcoma cell growth in vitro and trending towar
96 RI/II confirmed TNFRI-AlbudAb potency, human rhabdomyosarcoma cell line KYM-1D4 cytotoxicity, and hum
97 , we developed two resistant models from the rhabdomyosarcoma cell line Rh41: Rh41-807R, with acquire
98 ditions, while in a patient-derived alveolar rhabdomyosarcoma cell line, harbouring the diagnostic t(
101 ression in ERMS cells was confirmed in human rhabdomyosarcoma cell lines and prompted further analysi
104 gth E12 robustly restores differentiation in rhabdomyosarcoma cells and broadly suppresses multiple i
107 inhibition of PI3K-mTOR-AKT pathway in Rh30 rhabdomyosarcoma cells attenuated ICL-induced activation
108 entified that combination treatment arrested rhabdomyosarcoma cells in the G2 cell cycle prior to ind
111 oma xenograft to radiotherapy and sensitized rhabdomyosarcoma cells to the DNA interstrand cross-link
112 Both HT1080 cells overexpressing hTDP1 and rhabdomyosarcoma cells with elevated levels of hTdp1 wer
113 e million alveolar (Rh30) and embryonal (RD) rhabdomyosarcoma cells with stably transfected mCherry a
115 , YES1 and YAP1 interacted in the nucleus of rhabdomyosarcoma cells, and genetic or pharmacologic sup
117 the fusion and differentiation processes of rhabdomyosarcoma cells, representing a therapeutic vulne
118 is in both primary human muscle cells and RD rhabdomyosarcoma cells, we demonstrate that MyoD binds i
122 bryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma constitute the two major subtypes and e
123 tion of miR-1 and miR-133a into an embryonal rhabdomyosarcoma-derived cell line is cytostatic, thereb
124 mosomal translocation that leads to alveolar rhabdomyosarcoma development generates a novel TAD that
126 des two histolopathologic subtypes: alveolar rhabdomyosarcoma, driven by the fusion protein PAX3-FOXO
127 S-associated protein) is highly expressed in rhabdomyosarcoma, driving growth and survival when the u
128 Thus, MYOD1 p.Leu122Arg defines a subset of rhabdomyosarcomas eligible for high-risk protocols and t
129 ing of tumour-propagating cells in embryonal rhabdomyosarcoma, emergence of clonal dominance in T-cel
131 Wnt signaling is downregulated in embryonal rhabdomyosarcoma (ERMS) and contributes to the block of
133 , or gross residual (orbital only) embryonal rhabdomyosarcoma (ERMS) had 5-year failure-free survival
138 tein PAX3-FOXO1 or PAX7-FOXO1, and embryonal rhabdomyosarcoma (ERMS), which is genetically heterogene
140 patients with subset-one low-risk embryonal rhabdomyosarcoma (ERMS; stage 1/2 group I/II ERMS or sta
142 ymphoma), solid malignancies (neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, and osteosarcoma), and
143 tumors that affect children, particularly in rhabdomyosarcoma, Ewing sarcoma, and other round cell sa
144 criteria) in the following disease cohorts: rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, neuroblas
145 ubunit CHD4 is essential for fusion-positive rhabdomyosarcoma (FP-RMS) survival, but the mechanisms u
146 e signature we determined could discriminate rhabdomyosarcoma from muscle, revealing a subset of musc
149 therapeutic options for the pediatric cancer rhabdomyosarcoma have not improved significantly, especi
152 f origin for Sonic Hedgehog-driven embryonal rhabdomyosarcoma in an adipocyte-restricted conditional
155 e than three decades, standard treatment for rhabdomyosarcoma in Europe has included 6 months of chem
171 ock in the childhood muscle cancer embryonal rhabdomyosarcoma is often thought to hold promise as an
177 ipoma, leiomyoma, haemangioma) or malignant (rhabdomyosarcoma, melanotic neuroectodermal tumour of in
178 logic activities linked to PDGF signaling in rhabdomyosarcoma models and human sample collections.
181 ted satellite cells gave rise to pleomorphic rhabdomyosarcomas (MyoD-, Myogenin- and Desmin-positive)
182 ant peripheral-nerve sheath tumor (n = 7), 0 rhabdomyosarcoma (n = 2), and three synovial sarcomas (n
183 number of additional malignancies, including rhabdomyosarcoma, neuroblastoma, anaplastic large cell l
184 n-metastatic incompletely resected embryonal rhabdomyosarcoma occurring at unfavourable sites with un
185 onal study trials exist for the treatment of rhabdomyosarcoma, only very limited information is given
186 ne can lead to complete response in multiple rhabdomyosarcoma orthotopic patient-derived xenografts t
187 mphomas, astrocytomas, Ewing's sarcomas, and rhabdomyosarcomas (p<0.0001 in all cases), and osteosarc
190 cation that is the foundation of all present rhabdomyosarcoma protocols developed by the Children's O
192 g passage of the prototype strain, Nancy, on rhabdomyosarcoma (RD) cells, which express DAF but very
194 rawak, Malaysia, were characterised in human rhabdomyosarcoma (RD), neuroblastoma (SH-SY5Y) and perip
197 ene expression profiles of 101 primary human rhabdomyosarcomas revealed elevated PDGF-C and -D expres
198 cated in drug-sensitive and -resistant human rhabdomyosarcoma Rh30 cells, suggesting that our finding
201 uding gastrointestinal stromal tumor (GIST), rhabdomyosarcoma (RMS) and leiomyosarcoma (LMS), feature
202 OR) pathway is often aberrantly activated in rhabdomyosarcoma (RMS) and represents a promising therap
204 nely lost in advanced, poorly differentiated rhabdomyosarcoma (RMS) but characteristically expressed
205 PP242 cause catastrophic macropinocytosis in rhabdomyosarcoma (RMS) cells and cancers of the skin, br
206 GFBP-6 was found to promote the migration of rhabdomyosarcoma (RMS) cells in an IGF-independent manne
207 ntial element for the growth and survival of rhabdomyosarcoma (RMS) cells using a bar-coded, tetracyc
210 r tumors from diagnostic biopsies of primary rhabdomyosarcoma (RMS) contain relevant prognostic infor
233 ntify novel signaling pathways necessary for rhabdomyosarcoma (RMS) survival, we performed a loss-of-
234 e outcome of patients with intermediate-risk rhabdomyosarcoma (RMS) treated with standard VAC (vincri
236 e poor prognosis of metastatic and recurrent rhabdomyosarcoma (RMS) under the current regimen of poly
237 temsirolimus for additional investigation in rhabdomyosarcoma (RMS) when administered in combination
242 n aggressive metastatic disease in pediatric rhabdomyosarcoma (RMS), irrespective of histological sub
243 atients with incompletely resected embryonal rhabdomyosarcoma (RMS), undifferentiated sarcoma, and so
244 ribe an in vitro drug profiling platform for rhabdomyosarcoma (RMS), using a living biobank composed
245 g for new strategies to trigger apoptosis in rhabdomyosarcoma (RMS), we investigated the effect of tw
246 ession and underlying genetic aberrations in rhabdomyosarcoma (RMS), with special attention to clinic
255 from P2 MCMV-infected mice were pleomorphic rhabdomyosarcomas (RMS) harboring MCMV DNA, RNA, and pro
258 [a non-small-cell lung cancer (NSCLC) and a rhabdomyosarcoma] showed expression of highly phosphoryl
259 of disease affect outcome in paediatric non-rhabdomyosarcoma soft-tissue sarcoma (NRSTS), but no ris
260 , 6.21 cases per 1 million person-years) and rhabdomyosarcoma (standardized incidence ratio, 2.62; 95
261 overall survival rates of 95% on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III/IV.
264 oup, Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, and the National Wilms Tum
266 3/FOXO1 and PAX7/FOXO1 positive), Intergroup Rhabdomyosarcoma Study TNM stage, and age showed a signi
268 ediate-risk RMS enrolled onto the Intergroup Rhabdomyosarcoma Study-IV and the Children's Oncology Gr
270 eep miRNA profiling of the three major human rhabdomyosarcoma subtypes, along with cell lines and nor
271 ts of miR-1 and miR-133a are up-regulated in rhabdomyosarcomas, suggesting a causative role for these
272 ue in patients with relapsed Wilms tumor and rhabdomyosarcoma suggests that some patients may benefit
273 ue in patients with relapsed Wilms tumor and rhabdomyosarcoma suggests that some patients may benefit
275 specifically focus on embryonal and alveolar rhabdomyosarcoma, synovial sarcoma, and adult soft tissu
276 k to small blue round cell tumors (including rhabdomyosarcoma, synovial sarcoma, neuroblastoma, Ewing
277 al rhabdomyosarcoma and a human cell line of rhabdomyosarcoma that harbored activated mutations in NR
279 rexpression of the nuclear receptor NR4A1 in rhabdomyosarcomas that is sufficient to drive high expre
280 gested as potential targets for treatment of rhabdomyosarcoma, the most common soft tissue sarcoma in
281 se results point to the promise of enhancing rhabdomyosarcoma therapy using miRNAs as agents that med
285 ), a microtubule inhibitor currently used in rhabdomyosarcoma treatment regimens, resulted in a combi
286 showed a large variation in IGF-IR levels in rhabdomyosarcoma tumor specimens that were comparable wi
287 AX3-FKHR translocation to the development of rhabdomyosarcoma tumors has been further elucidated.
289 A KRAS(G12D)-induced zebrafish embryonal rhabdomyosarcoma was then used to assess the therapeutic
290 o molecular subtypes of the pediatric cancer rhabdomyosarcoma, we show that an exhaustive iterative s
292 ion of clonal expansion in neuroblastoma and rhabdomyosarcoma, whereas in Wilms tumor, they are late
294 uded patients aged 6 months to 21 years with rhabdomyosarcoma who were considered to be at high risk
295 We established a unique model of metastatic rhabdomyosarcoma with a high frequency of tumor occurren
297 cm), or both; those with any non-metastatic rhabdomyosarcoma with nodal involvement; and those with
298 inical samples of the skeletal muscle cancer rhabdomyosarcoma, with the highest expression found in t
299 ficantly enhanced sensitivity of a pediatric rhabdomyosarcoma xenograft to radiotherapy and sensitize